<DOC>
	<DOCNO>NCT02610348</DOCNO>
	<brief_summary>Primary Objective : To describe persistence Hep B antibody ( Ab ) 12 18 month age follow three-dose infant primary series vaccination either Hexaxim®/Hexyon®/Hexacima® Infanrix® hexa 2 , 4 6 month age follow Hep B vaccination birth .</brief_summary>
	<brief_title>Anti-Hep B Antibodies Age 12 18 Months After Hep B Vaccine Birth DTaP-IPV-Hep B-PRP-T Hexavalent Vaccine Concomitantly With Prevnar® 2 , 4 6 Months Age</brief_title>
	<detailed_description>Sera subject participate study PNA19 trial ( NCT00594347 ) parent legal representative give authorization use serum take child use study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Subjects receive 4 Hep B dose A3L12 ( i.e . one dose birth + three dos study 2 , 4 &amp; 6 month age ) Subjects participated PNA19 Subject 's parent give authorization use serum collect PNA19 future research The initial , birth date , gender subject consistent A3L12 PNA19 databases Subjects retention serum enough volume allow valid determination HBsAg antibody level .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Hexaxim®</keyword>
	<keyword>Hexyon®</keyword>
	<keyword>Hexacima®</keyword>
	<keyword>Prevnar®</keyword>
	<keyword>DTaP-IPV-HB-Hib hexavalent vaccine</keyword>
</DOC>